Last checked at 7 Jun 2021 07:00
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 7 June 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 4 June 2021 the Board of Synairgen granted options ('Options') over 831,725 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.42 per cent. of the Company's issued share capital.
Following this grant, Synairgen has 9,503,004 options in issue, representing 4.75 per cent. of the Company's issued share capital.
Included in the number of Options granted on 4 June 2021, the following Options were issued to directors:
Director | Options Issued |
Richard Marsden | 135,626 |
Dr. Phillip Monk | 97,953 |
John Ward | 105,487 |
Following the issue of the Options, the interests of the directors of the Company at
4 June 2021 are as follows:
Director | Total options | Ordinary shares | Total interest | Percentage holding of fully diluted share capital |
Richard Marsden | 2,817,576 | 754,667 | 3,572,243 | 1.71% |
Dr. Phillip Monk | 2,046,535 | 244,600 | 2,291,135 | 1.09% |
John Ward | 2,262,106 | 514,907 | 2,777,013 | 1.33% |
Simon Shaw | - | 1,531,239 | 1,531,239 | 0.73% |
Iain Buchanan | - | 112,741 | 112,741 | 0.05% |
Dr. Bruce Campbell | - | 322,830 | 322,830 | 0.15% |
Prof. Sir Stephen Holgate | - | 886,931 | 886,931 | 0.42% |
In addition, Jody Brookes, Richard Hennings and Victoria Tear, persons disclosing managerial responsibilities, were granted 62,460, 242,568 and 49,968 Options respectively on the same terms as above. The balance of the Options were granted to a number of employees.
The Options are issued under the Company's Long Term Incentive Plans and are exercisable up to 3 June 2031, subject to the achievement of appropriate performance criteria.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MK Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | Richard Marsden |
2. | Reason for notification | |
a) | Position / status | Chief Executive Officer |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
b) | Nature of the transaction | Award of Options under the Company's share plans |
c) | Price(s) and volume(s) | 135,626 Options awarded |
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 4 June 2021 |
f) | Place of the transaction | Outside a trading venue |
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | Dr Phillip Monk |
2. | Reason for notification | |
a) | Position / status | Chief Scientific Officer |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
b) | Nature of the transaction | Award of Options under the Company's share plans |
c) | Price(s) and volume(s) | 97,953 Options awarded
|
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 4 June 2021 |
f) | Place of the transaction | Outside a trading venue |
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | John Ward |
2. | Reason for notification | |
a) | Position / status | Chief Financial Officer |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
b) | Nature of the transaction | Award of Options under the Company's share plans |
c) | Price(s) and volume(s) | 105,487 Options awarded
|
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 4 June 2021 |
f) | Place of the transaction | Outside a trading venue |
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | Jody Brookes |
2. | Reason for notification | |
a) | Position / status | Head of Clinical Operations |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
b) | Nature of the transaction | Award of Options under the Company's share plans |
c) | Price(s) and volume(s) | 62,460 Options awarded
|
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 4 June 2021 |
f) | Place of the transaction | Outside a trading venue |
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | Victoria Tear |
2. | Reason for notification | |
a) | Position / status | Head of Laboratories |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
b) | Nature of the transaction | Award of Options under the Company's share plans |
c) | Price(s) and volume(s) | 49,968 Options awarded
|
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 4 June 2021 |
f) | Place of the transaction | Outside a trading venue |
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
a) | Name | Richard Hennings |
2. | Reason for notification | |
a) | Position / status | Chief Commercial Officer |
b) | Initial notification / amendment | Initial Notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Synairgen plc |
b) | LEI | 213800IMMTOPPDF8HD24 |
4. | Details of the transaction(s): | |
a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
b) | Nature of the transaction | Award of Options under the Company's share plans |
c) | Price(s) and volume(s) | 242,568 Options awarded
|
d) | Aggregated information Aggregated volume Price | n/a |
e) | Date of the transaction | 4 June 2021 |
f) | Place of the transaction | Outside a trading venue |